Rising uncertainty driven by US tariffs and proposed “most-favoured nation” pricing is prompting pharmaceutical companies to delay investment and product launches in Europe. US tariffs and pricing pressure are causing uncertainty for the pharma sector, which will slow investment decisions and delay patient access to new medicines in Europe, according to a new industry survey [...]
US tariffs and MFN pricing threaten pharma investment and access in Europe
